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Abstract
Chronic treatment-related adverse events adversely affect quality of life, treatment adherence, and clinical
outcomes of many patients taking imatinib. The ENRICH (Exploring Nilotinib to Reduce Imatinib Related
Chronic Adverse Events) study evaluated the effect of switching 52 such patients to nilotinib. Within 3 months
of switching, improvements in imatinib-related adverse events and quality of life and ongoing achievement and
maintenance of molecular and cytogenetic responses were observed.
Background: Many patients with chronic myeloid leukemia in chronic phase experience chronic treatment-related
adverse events (AEs) during imatinib therapy. These AEs can impair quality of life and lead to reduced treatment
adherence, which is associatedwith poor clinical outcomes.Patients and Methods: In the phase II ENRICH (Exploring
Nilotinib to Reduce Imatinib Related Chronic Adverse Events) study (N ¼ 52), the effect of switching patients with
imatinib-related chronic low-grade nonhematologic AEs from imatinib to nilotinib was evaluated. Results: Three
months after switching to nilotinib, 84.6% of the patients had overall improvement in imatinib-related AEs (primary
endpoint). Of 210 imatinib-related AEs identiﬁed at baseline, 62.9% had resolved within 3 months of switching to
nilotinib. Of evaluable patients, most had improvements in overall quality of life after switching to nilotinib. At screening,
65.4% of evaluable patients had a major molecular response (BCR-ABL1  0.1% on the International Scale). After
switching to nilotinib, the rate of the major molecular response was 76.1% at 3 months and 87.8% at 12 months.
Treatment-emergent AEs reported with nilotinib were typically grade 1 or 2; however, some patients developed more
serious AEs, and 8 patients discontinued nilotinib because of new or worsening AEs. Conclusion: Overall, results from
the ENRICH study demonstrated that switching to nilotinib can mitigate imatinib-related chronic low-grade non-
hematologic AEs in patients with chronic myeloid leukemia in chronic phase, in conjunction with acceptable safety and
achievement of molecular responses. This trial was registered at www.clinicaltrials.gov as NCT00980018.
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and poor long-term outcomes.4-7 Therefore, the proper manage-
ment of AEs is critical for ensuring optimal outcomes.1,3,6,8 When
treatment interruptions and reduced adherence result from
imatinib-related toxicities, switching patients to another tyrosine
kinase inhibitor (TKI) can improve tolerability and treatment
adherence, thereby optimizing responses.
Nilotinib is more potent and selective than imatinib,9 has
demonstrated superior efﬁcacy compared with imatinib,10-14 and is
associated with a safety proﬁle distinct from that of imatinib.10-14
Compared with imatinib, the incidence of nausea, vomiting, diar-
rhea, muscle spasms, and edema is lower with nilotinib, although
the incidence of rash, headache, and pruritus is higher with niloti-
nib.12 In a subset analysis of 95 patients with CML-CP who dis-
continued imatinib because of intolerance (>75% for grade 3/4
AEs) and switched to nilotinib, cross-intolerance (deﬁned as the
occurrence of the same AE with nilotinib that was associated with
intolerance to imatinib) was uncommon.15 In that study, no patient
required nilotinib dose reductions or discontinued nilotinib
treatment due to the same AE that had led to imatinib discontin-
uation.15 Cardiovascular AEs have been reported to varying degrees
with all TKIs approved for treatment of CML14,16-23 and were re-
ported more frequently with nilotinib than with imatinib in the
pivotal trial of frontline nilotinib versus imatinib (ENESTnd).13,14
The phase II ENRICH (Exploring Nilotinib to Reduce Imatinib
Related Chronic Adverse Events) study was conducted to evaluate
whether imatinib-related chronic low-grade nonhematologic AEs
could be improved and responses optimized by switching patients
from imatinib to nilotinib.
Patients and Methods
ENRICH was a phase II, single-arm, open-label, multicenter,
exploratory study to determine the effect of switching to nilotinib
on the AE proﬁle of patients with low-grade toxicities associated
with imatinib therapy (ClinicalTrials.gov identiﬁer,
NCT00980018).
Study Design and Treatments
Adults (aged  18 years) with CML-CP and an Eastern Coop-
erative Oncology Group performance status of  2 were eligible.
The patients had been treated with imatinib (any dose) for  3
months before screening and experienced a Common Terminology
Criteria for Adverse Events (CTCAE) grade 1 or 2 nonhematologic
AE during imatinib therapy that had persisted for > 2 months or
had recurred > 3 times despite best supportive care. The patients
were required to have achieved the following efﬁcacy milestones
with imatinib therapy: after 3 months, a complete hematologic
response (CHR); after 6 months, Phþ < 95% ( 20 metaphases
required for standard bone marrow cytogenetics); after 12 months,
Phþ < 35%; and after 18 months, Phþ 0% or BCR-ABL1  0.1%
on the International Scale (BCR-ABL1IS; documented within 3
months). Patients meeting any of the following criteria were
excluded: any grade  3 nonhematologic AE within 30 days of
screening; previous accelerated or blast phase; loss of a CHR or
cytogenetic response (CyR); previously documented T315I muta-
tion; previous treatment with any TKI other than imatinib;
impaired cardiac function (including congenital long QT syndrome
or a known family history of long QT syndrome, a history orpresence of clinically signiﬁcant ventricular or atrial tachyarrhyth-
mias, clinically signiﬁcant resting bradycardia, an inability to
monitor the QT interval by electrocardiography, Fridericia-
corrected QT > 450 ms on the baseline electrocardiogram,
myocardial infarction within 1 year of starting the study drug, or
other clinically signiﬁcant heart disease); impaired gastrointestinal
function or gastrointestinal disease that could signiﬁcantly alter
absorption of nilotinib; acute or chronic liver, pancreatic, or renal
disease; a history of a signiﬁcant bleeding disorder; pregnancy or
nursing; treatment with a cytochrome P450 3A4 inhibitor; or
medication with the potential to prolong the QT interval.
Enrolled patients received nilotinib 300 mg twice daily for 12
cycles (1 cycle ¼ 28 days) during the study. No washout period was
required between imatinib and nilotinib treatment. The patients
were followed up for safety evaluations for 28 days after the last dose
of study drug.
Endpoints and Assessments
Imatinib-related chronic low-grade (grade 1 or 2) non-
hematologic AEs, hereafter referred to as imatinib-related AEs,
were assessed on days 1 and 15 of cycle 1 and at the end of cycles
(EOC) 1, 2, 3, 6, 9, and 12. The primary endpoint of the study was
the percentage of patients with overall improvement in imatinib-
related AEs at EOC 3 after the switch to nilotinib. Overall
improvement was deﬁned as either a decrease in CTCAE grade or
resolution of  50% of a patient’s imatinib-related AEs. The sec-
ondary endpoints included the rate of complete CyR (CCyR;
deﬁned as negative ﬂuorescence in situ hybridization [FISH]
ﬁndings or 0% Phþ cells) among patients without CCyR at base-
line; the rate of major molecular response (MMR) at EOC 1, 2, 3,
6, 9, and 12; BCR-ABL1IS log changes following switch to niloti-
nib; the time to, and duration of, CCyR and MMR during the
study; the time to the ﬁrst documented and optimal improvement
in imatinib-related AEs; and safety.
The time to the ﬁrst documented improvement of imatinib-
related AEs was deﬁned as the interval from the ﬁrst dose of the
study drug until the ﬁrst documented decrease in CTCAE grade.
The time to optimal improvement of imatinib-related AEs was
deﬁned as the interval from the ﬁrst dose of the study drug until a
maximum decrease in the sum of the CTCAE grades of the events.
AEs with an onset date on or after the date of study drug initiation
or that had worsened or recurred during study treatment were
included in the analysis of AEs occurring during nilotinib treatment.
Serious AEs (SAEs) occurring at any point from the initiation of
study drug until 28 days after stopping study participation were also
analyzed. Nilotinib dose reductions were required for patients with
grade 3/4 AEs concerning white blood cells and platelets and grade
2 to 4 nonhematologic AEs. Discontinuation from the study was
required if any toxicity had not resolved after 28 days. AEs were
assessed using CTCAE, version 4.0.
The times to CCyR and MMR were deﬁned as the interval from
the ﬁrst dose of the study drug to the ﬁrst documented CCyR or
MMR, respectively. The duration of CCyR was deﬁned as the in-
terval from the ﬁrst documented CCyR to the date of the ﬁrst
documented loss of CCyR or study termination, whichever was
earlier. The duration of MMR was deﬁned similarly. Bone marrow
cytogenetic assessment was required at screening if noClinical Lymphoma, Myeloma & Leukemia May 2016 - 287
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288 -documentation was available that the patient had achieved the ef-
ﬁcacy milestones during imatinib therapy that were required for
study eligibility. For patients with < 18 months of previous ima-
tinib therapy and without CCyR at screening, additional bone
marrow cytogenetic assessments were required during the study.
Once CCyR was documented by cytogenetics, no additional bone
marrow assessments were required unless a loss of response was
suspected or early discontinuation was required before EOC 12.
Peripheral blood FISH was performed at EOC 1, 2, 3, 6, and 9
until achievement of CCyR and at EOC 12 for all patients.
The exploratory endpoints included a change in overall QOL and
in the MD Anderson Symptom Inventory Chronic Myeloid Leu-
kemia Module (MDASI-CML) score, both assessed at baseline and
at EOC 1, 3, 6, 9, and 12. For evaluation of overall QOL, the
patients rated their QOL within the previous 24 hours and the
previous 7 days on an 11-point scale by responding to the following:
“rate your quality of life within the last 24 hours on a scale of 0 to
10” and “rate your quality of life within the last 7 days on a scale of
0 to 10,” with an increasing QOL score indicating improvement.
The MDASI-CML module is a patient-reported outcome measure
for the evaluation of symptom burden in patients with CML and
comprises 20 core and CML-speciﬁc symptom items (ie, vomiting,
nausea, diarrhea, dry mouth, pain, drowsiness, shortness of breath,
sadness, difﬁculty remembering, disturbed sleep, distress, fatigue,
numbness, muscle soreness, swelling, malaise, rash or skin change,
bruising easily or bleeding, lack of appetite, and headache)3 and 6
interference items (ie, general activity, work, walking, enjoyment of
life, mood, and relationships with other people). After completion
of the present study, the MDASI-CML module was validated, and
headache was added as a CML-speciﬁc item.3 The patients scored
each symptom or interference item on an 11-point scale, with a
decreasing MDASI-CML score indicating improvement. For
MDASI-CML symptom items, a rating of 0 indicates “not present”
and 10, severity “as bad as you can imagine.” For MDASI-CML
interference items, a rating of 0 indicates “did not interfere” and
10, “interfered completely.”
Statistical Analysis
The efﬁcacy analyses included all patients who had received  1
dose of study drug. The safety analyses included all patients who had
received  1 dose of the study drug and had had  1 evaluable
postbaseline safety assessment. The primary endpoint was assessed
using a 95% conﬁdence interval (CI) using the normal approximation
to the binomial. The proportion of imatinib-related AEs with
improvement was assessed using a quasi-likelihood method24,25 that
accommodated the unknown covariance associated with measuring
the overall effect of AEs for individual patients. Times to CCyR,
MMR, ﬁrst documented improvement in any imatinib-related AE,
and optimal improvement in imatinib-related AEs were analyzed
using the Kaplan-Meier product limit method. The planned sample
size was 50 patients to assess the primary endpoint with a 2-sided 95%
CI within 14% of the true percentage. All statistical analyses were
performed using SAS software, version 9.1.3.
Ethics Statements
The present study was conducted in accordance with the
Declaration of Helsinki and local applicable laws and regulations.Clinical Lymphoma, Myeloma & Leukemia May 2016The institutional review board or independent ethics committee at
each participating study center approved the protocol. Each patient
provided written informed consent before study participation.
Results
Patients and Treatments
The ENRICH study was conducted across 15 centers in the
United States and 4 centers in Canada; 52 patients were enrolled
from December 10, 2009 to August 15, 2012 (study completion
date, December 27, 2012). The baseline demographics and char-
acteristics of all enrolled patients are listed in Table 1. All evaluable
patients had a CHR at baseline, and most patients had a CCyR and
an MMR at baseline (86.5% and 65.4%, respectively). Forty pa-
tients (76.9%) completed the study per protocol, and 12 dis-
continued early, 8 because of AEs (15.4%), 3 by withdrawal of
consent (5.8%), and 1 because the patient was lost to follow-up
(1.9%). The median duration of nilotinib exposure during the
study was 336 days (range, 6-617 days).
Impact of Switching to Nilotinib on Imatinib-Related AEs
Among the 52 patients, 210 imatinib-related AEs were identiﬁed
at baseline, including 154 grade 1 AEs and 56 grade 2 AEs. The
most common imatinib-related AE at baseline was fatigue (n ¼ 29;
13.8%), followed by diarrhea and nausea, each occurring in 20
patients (9.5%; Table 2).
Of the 210 imatinib-related AEs at baseline, 132 (62.9%) had
resolved, 13 (6.2%) had improved, 55 (26.2%) were unchanged,
and 6 (2.9%) had worsened at EOC 3. Information was missing for
4 AEs (1.9%; Figure 1A). Of the imatinib-related fatigue AEs, 16 of
29 (55.2%) had improved or resolved at EOC 3, as had 19 of 20
imatinib-related diarrhea AEs (95.0%) and 16 of 20 imatinib-
related nausea AEs (80.0%). Similarly,  50% of imatinib-related
AEs of muscle spasms, peripheral edema, periorbital edema,
arthralgia, myalgia, headache, dyspepsia, rash, face edema, weight
increase, pruritus, vomiting, bone pain, and amnesia had improved
or resolved by EOC 3. Of the 6 imatinib-related AEs that had
worsened by EOC 3, 5 had worsened from grade 1 to grade 2
(fatigue [n ¼ 2], pruritus [n ¼ 1], headache [n ¼ 1], and memory
impairment [n ¼ 1]) and 1 had worsened from grade 2 to grade 3
(generalized pain). At EOC 12, 151 of 210 imatinib-related AEs
(71.9%) had either improved or resolved, and 34 imatinib-related
AEs (16.2%) had resolved but then reappeared. The AE type that
most frequently resolved and reappeared was muscle spasms
(resolved and reappeared in 5 of 14 patients [35.7%]).
An overall improvement (resolution of, or reduction in, CTCAE
grade for  50% of a patient’s imatinib-related AEs) was observed
in 37 of 52 patients (71.2%) at EOC 1 (Figure 1B). By EOC 3, 7
additional patients had achieved an overall improvement. Thus, the
total number of patients with an overall improvement at EOC 3
(primary endpoint) was 44 of 52 (84.6%; 95% CI, 72.5%-92.0%).
No additional patients achieved an overall improvement after EOC
3, and all 44 patients with overall improvement at EOC 3 main-
tained the improvement through EOC 12. Thus, the proportion of
patients with overall improvement was 84.6% at all points beyond
EOC 3. The estimated median time to the ﬁrst improvement of any
imatinib-related AE was 1 month (95% CI, 0.3-1.0 month), and
the estimated median time to optimal (ie, maximum) improvement
Table 1 Patient Demographic and Baseline Characteristics
(N [ 52; Nilotinib 300 mg BID)
Characteristic Value
Age (years)
Mean 51.7
Range 34-82
Male gender (%) 50.0
Caucasian (%) 86.5
ECOG performance status (%)
0 44.2
1 48.1
2 7.7
Time since diagnosis (mo)
Median 31.4
Range 3.0-179.3
Previous imatinib dose (mg/d)
Median 400
Range 300-800
Duration of previous imatinib treatment (mo)
Median 31.1
Range 2-145a
Patients with complete cytogenetic responseb (%) 86.5
Patients with major molecular response (%) 65.4
Imatinib-related AEs at baseline (n)
Median 3
Range 1-11
Imatinib-related AEs per patient at baseline (%)
1 5.8
2 21.2
3 30.8
 4 42.3
Abbreviations: AE ¼ adverse event; BID ¼ twice daily; ECOG ¼ Eastern Cooperative Oncology
Group.
aOne patient with < 3 months of previous imatinib treatment was enrolled and treated (protocol
deviation).
bBased on prestudy results, ﬂuorescence in situ hybridization assessment at screening, and
bone marrow aspirate at screening.
Jorge E. Cortes et alof imatinib-related AEs was 1.9 months (95% CI, 1.0-2.1 months).
No patient had an overall worsening (deﬁned as an increase in
CTCAE grade for  50% of imatinib-related AEs) at any time
point. In 30 patients (57.7%), all imatinib-related AEs had
improved at EOC 12, although 3 patients (5.8%) did not have
improvement in any imatinib-related AE at EOC 12 (Figure 1C).
As expected, a negative correlation was found at all observation
points (at EOC 3, r ¼ 0.42) between the number of imatinib-
related AEs and the proportion of AEs that improved after
switching to nilotinib (ie, patients with a higher number of
imatinib-related AEs were less likely to achieve overall
improvement).
AEs During Nilotinib Treatment
After switching to nilotinib, 51 patients (98.1%) developed new
or worsening AEs, including AEs with a suspected relationship to
the study treatment in 44 patients (84.6%). The most common newor worsening nonhematologic AEs (regardless of a relationship to
the study drug) of any grade were fatigue (19 of 52 patients;
36.5%), rash (18 of 52 patients; 34.6%), headache (17 of 52 pa-
tients; 32.7%), constipation (14 of 52 patients; 26.9%), arthralgia
(13 of 52 patients; 25.0%), nausea (12 of 52 patients; 23.1%), and
pruritus (12 of 52 patients; 23.1%). The most common AEs sus-
pected to be related to study treatment were headache (14 of 52
patients; 26.9%), rash (13 of 52 patients; 25.0%), fatigue (12 of 52
patients; 23.1%), and pruritus (11 of 52 patients; 21.2%). Although
most AEs reported during nilotinib treatment were grade 1 or 2, 20
patients (38.5%) had grade 3 AEs during nilotinib treatment
(Table 3), and 1 patient experienced a grade 4 AE of cardiac arrest.
This patient had a history of hypertension before study entry and no
other known cardiovascular risk factors. Grade 1 QT prolongation
(450-480 ms) was observed in 1 patient; QT or Fridericia-corrected
QT > 500 ms was not observed in any patient.
A total of 9 patients (17.3%) had SAEs. These included 3 pa-
tients with infection (2 with a suspected study drug relationship [1
patient also had ovarian torsion]; the third patient had acute
cholecystitis and hypotension); 2 patients with pancreatitis (both
with a suspected study drug relationship); the patient noted in the
previous paragraph with cardiac arrest (suspected study drug
relationship); 1 patient with injury (scapula fracture/cartilage
injury); 1 patient with facial palsy and coronary artery disease; and
1 patient with arthralgia (suspected study drug relationship), pain
(suspected study drug relationship), pleural effusion (suspected
study drug relationship), arteriosclerosis, malignant mesothelioma,
and pleural ﬁbrosis. None of the 3 patients with SAEs of infection
had grade 3/4 neutropenia at the time of the infection.
Twenty-three patients (44.2%) had AEs that led to dose inter-
ruption or reduction. Of the 8 patients who discontinued because of
AEs (15.4%), 2 discontinued because of hyperglycemia (neither had
a known history of diabetes). Of the remaining 6 patients, 1 dis-
continued because of cardiac arrest (SAE), hypercholesterolemia,
and hypotension; 1 because of pleural effusion (SAE), malignant
mesothelioma (SAE), and pleural ﬁbrosis (SAE); 1 because of
headache, sore mouth, and stomach pain; and 1 each for cough,
vertigo, and myasthenia gravis. Of the AEs leading to discontinu-
ation of study treatment, all, except for malignant mesothelioma,
pleural ﬁbrosis, and myasthenia gravis, were suspected to be related
to the study drug.
Response
Forty-two patients underwent bone marrow cytogenetic assess-
ments at screening, and 7 patients did not have CCyR at baseline
(13.5% of 52 patients; median previous imatinib treatment dura-
tion, 4.8 months). All 7 patients had achieved CCyR by EOC 6 (as
assessed by FISH). Of these 7 patients, the estimated median time
to achieve CCyR was 1.9 cycles and the median duration of CCyR
was 282 days.
At screening, 34 patients (65.4%) had an MMR. Regarding
deeper MR, 19 (36.5%) had MR4 (BCR-ABL1IS  0.01%) and 10
(19.2%) had MR4.5 (BCR-ABL1IS  0.0032%; Figure 2). Of the
18 patients without an MMR at screening (median previous ima-
tinib treatment duration, 9.5 months), 11 (61.1%) achieved an
MMR by EOC 3, and 15 (83.3%) achieved MMR at any point
during the study. The estimated median time to achieve an MMRClinical Lymphoma, Myeloma & Leukemia May 2016 - 289
Table 2 Change in Most Frequently Reported (‡ 3 Patients) Imatinib-Related Chronic Low-Grade (Grade 1 or 2) Nonhematologic AEs at Baseline
Imatinib-
Related AE
Patients
With AEs at
Baseline (n)a
Change in Imatinib-Related AEs After Switching to Nilotinib
EOC 1 EOC 3 EOC 12
Resolved Resolved Improved Unchanged Worsened Resolved Improved Unchanged Worsened
Resolved,
Reappeared
Fatigue 29 5 (17.2) 10 (34.5) 6 (20.7) 10 (34.5) 2 (6.9) 11 (37.9) 6 (20.7) 10 (34.5) 1 (3.4) 3 (10.3)
Diarrhea 20 14 (70.0) 19 (95.0) 0 1 (5.0) 0 19 (95.0) 0 1 (5.0) 0 4 (20.0)
Nausea 20 14 (70.0) 16 (80.0) 0 3 (15.0) 0 16 (80.0) 0 3 (15.0) 0 4 (20.0)
Muscle spasms 14 8 (57.1) 12 (85.7) 0 2 (14.3) 0 12 (85.7) 0 2 (14.3) 0 5 (35.7)
Peripheral edema 13 6 (46.2) 8 (61.5) 2 (15.4) 3 (23.1) 0 8 (61.5) 2 (15.4) 3 (23.1) 0 0
Periorbital edema 13 5 (38.5) 9 (69.2) 0 3 (23.1) 0 9 (69.2) 0 3 (23.1) 0 0
Arthralgia 10 4 (40.0) 6 (60.0) 1 (10.0) 3 (30.0) 0 6 (60.0) 1 (10.0) 3 (30.0) 0 2 (20.0)
Myalgia 9 5 (55.6) 6 (66.7) 0 3 (33.3) 0 6 (66.7) 0 3 (33.3) 0 2 (22.2)
Headache 8 1 (12.5) 4 (50.0) 0 3 (37.5) 1 (12.5) 4 (50.0) 0 2 (25.0) 2 (25.0) 2 (25.0)
Dyspepsia 4 2 (50.0) 2 (50.0) 0 2 (50.0) 0 3 (75.0) 0 1 (25.0) 0 1 (25.0)
Rash 4 1 (25.0) 2 (50.0) 0 2 (50.0) 0 3 (75.0) 0 1 (25.0) 0 2 (50.0)
Face edema 4 3 (75.0) 3 (75.0) 0 1 (25.0) 0 3 (75.0) 0 1 (25.0) 0 1 (25.0)
Weight increase 4 1 (25.0) 3 (75.0) 0 1 (25.0) 0 4 (100.0) 0 0 0 0
Insomnia 4 1 (25.0) 1 (25.0) 0 3 (75.0) 0 1 (25.0) 0 3 (75.0) 0 0
Pruritus 3 2 (66.7) 2 (66.7) 0 0 1 (33.3) 2 (66.7) 0 0 1 (33.3) 2 (66.7)
Vomiting 3 3 (100.0) 3 (100.0) 0 0 0 3 (100.0) 0 0 0 0
Abdominal pain 3 1 (33.3) 1 (33.3) 0 1 (33.3) 0 1 (33.3) 0 1 (33.3) 0 0
Bone pain 3 2 (66.7) 3 (100.0) 0 0 0 3 (100.0) 0 0 0 1 (33.3)
Amnesia 3 3 (100.0) 3 (100.0) 0 0 0 3 (100.0) 0 0 0 0
Data presented as n (%).
Abbreviations: AE ¼ adverse event; EOC ¼ end of cycle.
aFor each AE type, each AE occurred in a distinct patient (ie, the number of events was equal to the number of patients with that AE type).
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Figure 1 Effects on Imatinib-Related Chronic Low-Grade
Nonhematologic Adverse Events (AEs). (A) Change in
Status of Imatinib-Related AEs at End of Cycle (EOC) 1
and 3 Relative to Baseline (Percentages Were Derived
From the 210 Total Imatinib-Related AEs Reported at
Baseline). Proportion of Imatinib-Related AEs With
Improvement at (B) EOC 1 and (C) EOC 12 for Each
Patient
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Jorge E. Cortes et alwas 2.8 cycles. The median MMR duration among the patients who
had achieved an MMR during the study was 253 days. Four pa-
tients who achieved an MMR during the study later lost the MMR;
no patient with an MMR at screening lost it during the study. Of
the 41 patients evaluable for MR at EOC 12, 36 (87.8%) had an
MMR, 30 (73.2%) had MR4, and 17 (41.5%) had MR4.5.
At screening, the median BCR-ABL1IS level reduction was 3.375
(range, 5.13 to 0.64 reduction). Among 46 evaluable patients at
EOC 3, the median BCR-ABL1IS level reduction was 4.010 (range,
5.04 to 1.45 reduction), representing a median log reduction from
study baseline of 0.413 (range, 2.21 reduction to 0.39 increase).Among 41 evaluable patients at EOC 12, the median BCR-ABL1IS
level reduction was 4.379 (range, 5.32 to 2.36 reduction), repre-
senting a median log reduction from study baseline of 0.527 (range,
3.08 reduction to 0.45 increase).
Changes in QOL and MDASI-CML Scores
Throughout the study, QOL improvements relative to baseline
were observed in most evaluable patients, although a few patients
had worsening QOL relative to baseline (Figure 3). Among 43
patients evaluable for a change in QOL at EOC 1 relative to
baseline, the mean QOL scores for the previous 24 hours and the
previous 7 days were 7.0 (SD, 2.37) and 6.8 (SD, 2.06), respec-
tively, at EOC 1, compared with 6.3 (SD, 2.11) and 6.1 (SD, 2.19),
respectively, at baseline. Considering all patients, 50.0% and 44.2%
had improved QOL scores for the previous 24 hours and the pre-
vious 7 days at EOC 1 relative to baseline, 13.5% and 15.4% had
unchanged QOL scores, and 19.2% and 23.1% had worse QOL
scores, respectively (17.3% of patients were not evaluable for the
change in QOL from baseline to EOC 1). Among 36 patients
evaluable for changes in QOL at EOC 12, the mean overall QOL
score for the previous 24 hours was 8.0 (SD, 2.00) and for the
previous 7 days was 7.8 (SD, 2.04). Considering all the patients,
57.7% and 50.0% had improved QOL scores for the previous 24
hours and previous 7 days at EOC 12 relative to baseline, 3.8% and
5.8% had unchanged QOL scores, and 7.7% and 13.5% had worse
QOL scores, respectively (30.8% of the patients were not evaluable
for a change in QOL from baseline to EOC 12).
At baseline, the mean MDASI-CMLespeciﬁc symptom score
and mean MDASI-CML interference item score were 3.07
(SD, 2.03) and 3.92 (SD, 2.78), respectively. Improvements in both
MDASI-CML scores relative to baseline were observed throughout
the study (Figure 4). Among 38 patients evaluable for a change in
MDASI-CML scores at EOC 1, the speciﬁc symptom scores
decreased by a mean of 1.62 (SD, 2.22) relative to baseline, and the
interference item scores decreased by a mean of 1.66 (SD, 3.05)
relative to baseline. Among 35 patients evaluable for a change in
MDASI-CML scores at EOC 12, speciﬁc symptom and interference
item scores decreased by a mean of 1.59 (SD, 1.95) and 1.35
(SD, 2.86), respectively, relative to baseline.
Discussion
In the ENRICH study, switching from imatinib to nilotinib led
to improvements in imatinib-related AEs in most patients. Within 1
month after switching to nilotinib, most imatinib-related AEs had
either resolved or improved, and by 3 months, the frequency of the
AEs that had improved increased further. New AEs were reported
during nilotinib therapy, including SAEs; however, the overall QOL
and MDASI-CML scores generally improved throughout the study.
Nilotinib therapy also resulted in effective disease control, as evi-
denced by the maintenance and/or achievement of CyR and MR in
most patients.
The observed improvements in QOL andMDASI-CML scores in
the present study were consistent with those from previous reports,
demonstrating the impact of AEs onQOL. Low-grade AEs, including
gastrointestinal disorders (eg, nausea and diarrhea), blood and
lymphatic system disorders (eg, thrombocytopenia and neutropenia),
musculoskeletal disorders (eg, muscle spasms and arthralgia),Clinical Lymphoma, Myeloma & Leukemia May 2016 - 291
Table 3 Patients With Grade 3 AEs Reported During Treatment With Nilotinib (N [ 52)a
AE
Grade 3 Total Frequency (Any Grade)
Any Cause
Suspected Relationship
to Study Drug Any Cause
Suspected Relationship
to Study Drug
Any AE 20 (38.5) 16 (30.8) 51 (98.1) 44 (84.6)
Nonhematologic AE
Rash 3 (5.8) 2 (3.8) 18 (34.6) 13 (25.0)
Arthralgia 2 (3.8) 2 (3.8) 13 (25.0) 6 (11.5)
Hypotension 2 (3.8) 1 (1.9) 3 (5.8) 1 (1.9)
Pruritus 1 (1.9) 1 (1.9) 12 (23.1) 11 (21.2)
Myalgia 1 (1.9) 0 4 (7.7) 2 (3.8)
Bronchitis 1 (1.9) 1 (1.9) 2 (3.8) 1 (1.9)
Gastroenteritis 1 (1.9) 1 (1.9) 2 (3.8) 1 (1.9)
Pain 1 (1.9) 0 2 (3.8) 1 (1.9)
Pneumonia 1 (1.9) 0 2 (3.8) 1 (1.9)
Rash erythematous 1 (1.9) 1 (1.9) 2 (3.8) 2 (3.8)
Rash exfoliative 1 (1.9) 1 (1.9) 2 (3.8) 2 (3.8)
Rash papular 1 (1.9) 1 (1.9) 2 (3.8) 2 (3.8)
Arteriosclerosis 1 (1.9) 0 1 (1.9) 0
Cartilage injury 1 (1.9) 0 1 (1.9) 0
Cholecystitis acute 1 (1.9) 0 1 (1.9) 0
Dehydration 1 (1.9) 1 (1.9) 1 (1.9) 1 (1.9)
Intervertebral disc protrusion 1 (1.9) 0 1 (1.9) 0
Malignant mesothelioma 1 (1.9) 0 1 (1.9) 0
Menorrhagia 1 (1.9) 0 1 (1.9) 0
Pancreatitis 1 (1.9) 1 (1.9) 1 (1.9) 1 (1.9)
Pancreatitis acute 1 (1.9) 1 (1.9) 1 (1.9) 1 (1.9)
Pleural effusion 1 (1.9) 1 (1.9) 1 (1.9) 1 (1.9)
Pleural ﬁbrosis 1 (1.9) 0 1 (1.9) 0
Rheumatoid arthritis 1 (1.9) 0 1 (1.9) 0
Scapula fracture 1 (1.9) 0 1 (1.9) 0
Tendon rupture 1 (1.9) 0 1 (1.9) 0
Wound infection, bacterial 1 (1.9) 0 1 (1.9) 0
Wound infection,
staphylococcal
1 (1.9) 0 1 (1.9) 0
Laboratory abnormalities
Hyperglycemia 2 (3.8) 2 (3.8) 4 (7.7) 4 (7.7)
Hypokalemia 1 (1.9) 1 (1.9) 3 (5.8) 3 (5.8)
Hypophosphatemia 1 (1.9) 1 (1.9) 3 (5.8) 2 (3.8)
Lipase increase 1 (1.9) 1 (1.9) 3 (5.8) 3 (5.8)
Blood bilirubin increase 1 (1.9) 1 (1.9) 2 (3.8) 2 (3.8)
Hyperuricemia 1 (1.9) 0 2 (3.8) 0
Data presented as n (%).
Abbreviation: AE ¼ adverse event.
aOne grade 4 event (cardiac arrest, with suspected relationship to study drug) was reported during treatment with nilotinib.
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292 -psychiatric disorders (eg, insomnia and anxiety), and general disorders
and administration-site conditions (eg, fatigue and peripheral edema),
have been shown to negatively affect health-related QOL in patients
with CML-CP receiving long-term TKI therapy.26 Speciﬁcally, a
survey identiﬁed fatigue, muscle cramps, and swelling among the
factors that most affected QOL.8 In the present study, fatigue andClinical Lymphoma, Myeloma & Leukemia May 2016muscle cramps were among the most frequently reported imatinib-
related AEs, and fatigue was also the most frequently observed AE
during nilotinib therapy. Because of the potential impact of AEs on
QOL and treatment adherence,1-3,8,26 adequate management of
chronic low-grade AEs is crucial for optimizing the outcomes of pa-
tients with CML-CP. In the present study, most imatinib-related AEs
Figure 2 Molecular Response (MR) After Switch to Nilotinib (N [ 52). Rates of Major MR (MMR), MR4, and MR4.5 Were Calculated
Among Evaluable Patients at Each End of Cycle (EOC) Point. Of the 52 Patients, 15 Did Not Have Results for ‡1 Time Point
Shown. MMR [ BCR-ABL1IS £ 0.1%; MR4 [ BCR-ABL1IS £ 0.01%; MR4.5 [ BCR-ABL1IS £ 0.0032%
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Jorge E. Cortes et alresolved after the switch to nilotinib, although a few imatinib-related
AEs worsened or recurred with nilotinib therapy. These results are
consistent with previous data15 showing minimal cross-intolerance
between imatinib and nilotinib and suggesting that switching to
nilotinib could be an effective option for managing such events for
most patients.
Most patients developed new AEs after switching to nilotinib.
Most treatment-emergent AEs were grade 1/2; however, some pa-
tients developed grade 3/4 AEs, SAEs, or AEs leading to discon-
tinuation of study treatment. Because the patients in the present
study had only low-grade AEs before switching to nilotinib, the
beneﬁts of nilotinib must be considered together with the potential
risk of developing new AEs. The treatment-emergent AEs observed
in the present study were consistent with the known safety proﬁle of
nilotinib.10-12,14 Similar to the pattern of AEs observed in the
present study, the most frequently reported AEs in a previous trial of
second-line nilotinib for patients with imatinib resistance or intol-
erance were grade 1/2 rash, pruritus, nausea, fatigue, headache, and
constipation.11 Although in the present study, the general trend was
favorable, additional evaluation is needed to determine the impact
of new AEs on QOL for patients switching from imatinib to
nilotinib, in particular, because almost one-third of the patients
were not evaluable for a change in QOL at 12 months. In addition
to these more common AE types,10-12,14,17 a higher incidence of
cardiovascular AEs has been shown to result from long-term nilo-
tinib compared with long-term imatinib.13,14,17 In the present
study, cardiovascular SAEs of cardiac arrest, arteriosclerosis, and
coronary artery disease were observed in 1 patient each. Because the
present study was completed after a median of z 12 months of
nilotinib therapy, the long-term incidence of cardiovascular AEs and
SAEs in this patient population remains unknown. Somebiochemical abnormalities that have been reported to occur with
nilotinib therapy (ie, lipid and glucose elevations)27 are modiﬁable
cardiovascular risk factors.28 Thus, it is important that patients with
CML receive proper monitoring and management of cardiovascular
risk factors and comorbidities during treatment with any TKI.16
Although the present trial was not designed to monitor lipid
levels, glucose levels were recorded during the course of the study.
Switching to nilotinib also resulted in CyR and MR in this pa-
tient population. Importantly, the ENRICH study eligibility criteria
excluded patients with treatment failure, as deﬁned by the CML
management recommendations in place at the time (European
LeukemiaNet 2009 recommendations29); thus, all enrolled patients
were responding (optimally or suboptimally29) to frontline imatinib
therapy at the switch to nilotinib. Although it was not possible to
evaluate whether switching to nilotinib led to improvements in
patients’ response levels compared with the response they would
have achieved with continued imatinib therapy, the high rates of
MR and CyR observed after switch indicate that nilotinib therapy
was effective in this patient population. Most patients without
MMR at baseline achieved MMR during the study, and no patient
who entered the study with MMR lost it with nilotinib treatment.
Among evaluable patients at EOC 12, most had MR,4 and the
median BCR-ABL1IS level decreased by more than one-half log from
study baseline. Additionally, all 7 patients without CCyR at baseline
achieved CCyR after switching to nilotinib (although considering
the short duration of previous imatinib therapy for these 7 patients,
some of them might have eventually achieved CCyR with continued
imatinib treatment). These ﬁndings are consistent with several
studies in which patients with a suboptimal MR, resistance, or
intolerance to imatinib achieved improved responses after switching
to nilotinib. Furthermore, in previous studies, the higher responseClinical Lymphoma, Myeloma & Leukemia May 2016 - 293
Figure 3 Change in Overall Quality of Life (QOL). For Each End of Cycle (EOC) Point, the Proportion of Patients Reporting Better,
Unchanged, or Worse QOL Relative to Baseline Was Calculated Based on the Total Patient Population (N [ 52). QOL Was
Evaluated at Each EOC Point for the (A) Previous 24 Hours and (B) Previous 7 Days
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Figure 4 Mean Change in MD Anderson Symptom Inventory Chronic Myeloid Leukemia Module (MDASI-CML) Scores. For Each End of
Cycle (EOC) Point, the Mean Change in MDASI-CML Speciﬁc Symptom and MDASI-CML Interference Item Scores Relative to
Baseline Were Calculated Among Evaluable Patients. A Decrease in MDASI-CML Score Indicates Improvement
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Jorge E. Cortes et alrates on nilotinib were associated with improved long-term clinical
outcomes.11,30-32 Overall, the results from the ENRICH study have
demonstrated the positive effect of switching to nilotinib in a pa-
tient population not previously studied.
Conclusion
Overall, the results from the ENRICH study supported a positive
effect of switching to nilotinib for some patients with chronic low-
grade nonhematologic AEs during imatinib therapy. The optimal
course of therapy for each patient with CML-CP must be deter-
mined through consideration of several factors, including imatinib-
related AEs, potential nilotinib-related AEs, the relative efﬁcacy of
nilotinib versus imatinib, and the relative effect of each drug on
overall QOL and treatment adherence.
Clinical Practice Points
 It is well known that many patients with CML-CP treated with
imatinib experience chronic low-grade AEs.
 Before the approval of second-generation TKIs, patients experi-
encing such AEs with imatinib therapy had no treatment
options.
 In the registration study for nilotinib (ClinicalTrials.gov identi-
ﬁer, NCT00109707) in patients with resistance and/or intoler-
ance to imatinib, only patients with recurring grade 3/4 AEs or
intolerance to imatinib doses of 600 to 800 mg/day were
included.
 That study was conducted before second-generation TKIs had
been approved, and imatinib dose escalation was the only option
for patients with resistance, outside of a clinical trial. Thus,
although several approved TKI options are now available for
patients with resistance or intolerance to imatinib, no clinical
trial has ever evaluated a switch to nilotinib for patients with
chronic low-grade AEs from imatinib. The ENRICH study was
conducted speciﬁcally to address this question.
 For patients with these chronic low-grade treatment-related AEs
from imatinib therapy, switching to nilotinib provided
improvement of many of these AEs, improved patient QOL, and
led to the achievement of CyR and MR.
 With many TKI options now available to physicians who treat
patients with CML, these results indicate that nilotinib could be
a tolerable and effective treatment option for those patients
experiencing chronic, low-grade AEs during imatinib therapy.Acknowledgments
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